- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01385644
A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis (MSC in IPF)
A Phase I Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
The primary objective of this study is to establish the feasibility and safety of infusions of placental Mesenchymal Stem Cells (MSC) from related or unrelated HLA identical or HLA mismatched donors in the treatment of Idiopathic Pulmonary Fibrosis (IPF).
The secondary objectives are to document changes in lung function, 6 minute walk distance (6MWD), gas exchange and radiological appearance following infusion of MSC over a six month evaluation period.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4032
- The Prince Charles Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female from 40 to 80 years of age (Note: see exclusion 13 regarding women of child-bearing potential).
Diagnosis of IPF based on the following criteria in accordance with American Thoracic Society/European Respiratory Society (ATS-ERS) guidelines for diagnosing
IPF:
Definite or probable usual interstitial pneumonia confirmed on surgical lung biopsy (SLB)
or
In absence of SLB, all of the following "major criteria"
- High resolution CT scan (HRCT) showing definite findings for IPF (bibasilar reticular abnormalities with minimal ground glass opacities)
- Absence of other causes of IPF including drug toxicities, environmental exposure and connective tissue disease
- Abnormal pulmonary function tests including evidence of a restrictive ventilatory impairment and impaired gas exchange
- Transbronchial biopsy or BAL suggesting no features of an alternative diagnosis and three of four of the following "minor criteria"
- Age greater than 50 years
- Insidious onset of otherwise unexplained dyspnea on exertion
- Duration of illness greater than 3 months
- Bibasal, inspiratory crackles
Within 90 days of study enrolment, diagnosis must be confirmed by HRCT chest.
- Honeycombing greater than 5% in 0 - 3 lung zones (each lung divided into 3 zones - 1) at the level of the carina 2) highest point of right hemi diaphragm and 3) mid way between these two levels) as assessed on HRCT.
- Forced vital capacity (FVC) greater than 50 of predicted with a ratio of forced expiratory volume in 1 second to FVC (FEV1/FVC) greater than 0.7 (Pulmonary function tests must be completed no more than 90 days before screening).
- Diffusing capacity for carbon monoxide (DLCO) greater than 25% of predicted capacity.
- Ability to perform a 6-Minute Walk Test (6MWT) at screening.
- Competency to understand the information given in the Human Research and Ethics Committee (HREC) approved ICF and must sign the form prior to the initiation of any study procedures.
Exclusion Criteria:
- Diagnosis of an interstitial lung disease (ILD) or restrictive lung disease other than IPF.
Obstructive lung disease as determined by evidence of airflow obstruction on HRCT or physiologic criteria including:
FEV1/FVC ratio less than 0.7 Residual volume (RV) greater than 120% by plethysmography or significant (verified by radiologist) emphysema on HRCT if plethysmography not available Evidence of reactive airway disease by change in FEV1 of greater than 12% following bronchodilator challenge
- Evidence of sustained improvement of IPF condition defined as improvement from pre-therapy pulmonary function tests (PFTs) observed with two or more successive post-therapy PFTs over the year prior to randomization.
- Active or recent (less than 60 days prior to enrolment) significant respiratory tract infection, or a history of frequent (greater than 2 per year for the last 2 years) infective exacerbations of IPF.
- Hospitalization within 60 days of screening for an acute exacerbation of IPF (AE-IPF).
- Chronic heart failure (NYHA class III/IV) or known left ventricular ejection fraction less than 25%.
Chronic treatment with the following drugs prescribed for IPF (within 4 weeks of randomization):
oral corticosteroids (greater than 20 mg/day of prednisone or equivalent), immunosuppressive or cytotoxic drugs, antifibrotic drugs, chronic use of N-acetylcysteine
- Acute or chronic impairment (other than dyspnea) which limits the ability to comply with study requirements and procedures including the 6MWD
- Chronic treatment with immunosuppressive, cytotoxic, or antifibrotic drugs including pirfenidone, D-penicillamine, colchicine, cyclosporine A, TNF-alpha antagonists, imatinib, interferon-gamma, cyclophosphamide, or azathioprine within 30 days of randomization.
- Subject requires hemodialysis, peritoneal dialysis or hemofiltration.
- Systolic blood pressure less than 85 mmHg.
- History of malignancies within the past 5 years, with the exception of squamous or basal cell carcinoma of the skin or successfully treated in situ carcinoma of the cervix.
- Female who is of child-bearing potential.
- Known history of alcohol abuse within 1 year of enrolment.
- Participation in a clinical study involving another investigational drug or device within 28 days of screening.
- Co-morbid condition or illness limiting life expectancy to less than 1 year at time of screening.
- Serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with treatment, assessment or compliance with the protocol.
- Significant hypoxemia or hypercapnia at rest on room air as defined by a PaO2 less than 55mmHg or PaCO2 greater than 50mmHg.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1*10^6 MSC / kg
Placental MSC
|
MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane.
The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A).
These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
|
EXPERIMENTAL: 2*10^6 MSC / kg
Placental MSC
|
MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane.
The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A).
These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Demonstrated Acute Adverse Events Following Infusion
Time Frame: 4 hours post-infusion
|
Acute adverse events following infusion was defined as the development of anaphalaxis and/or a 25% increase or decrease from baseline of hemodynamic measurements.
|
4 hours post-infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in Lung Function as Assessed by FVC Compared to Baseline
Time Frame: 6 months post MSC infusion
|
Forced Vital Capacity (FVC) was measured and reported as a percentage of predicted and comapred from 6 months post-infusion to baseline
|
6 months post MSC infusion
|
Percentage Change in 6 Minute Walk Distance Compared to Baseline
Time Frame: Baseline and 6 months post MSC infusion
|
At 6 months 6 Minute Walk Distance was mesured and compared as a percentage to baseline
|
Baseline and 6 months post MSC infusion
|
Percentage Change in Lung Function as Assessed by DLCO Compared to Baseline
Time Frame: 6 months post MSC infusion
|
DLCO was measured as a percentage of predicted, and the percentage change between 6 months post-infusion and baseline is reported.
|
6 months post MSC infusion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Daniel Chambers, MBBS MRCP FRACP MD, The Prince Charles Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HREC/09/QPCH/105
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Placental MSC
-
Zeynep Kamil Maternity and Pediatric Research and...Unknown
-
Ain Shams UniversityCompletedCesarean Section ComplicationsEgypt
-
Hillel Yaffe Medical CenterCompleted
-
University Hospital, MontpellierRecruiting
-
Zeynep Kamil Maternity and Pediatric Research and...Completed
-
Instituto Materno Infantil Prof. Fernando FigueiraCompletedManagement of DeliveryBrazil
-
Istanbul Bakirkoy Maternity and Children Diseases...CompletedPostpartum HaemorrhageTurkey
-
Mount Sinai Hospital, CanadaOntario Mental Health FoundationUnknown
-
University of FlorenceActive, not recruiting
-
University of RochesterCompletedPregnancy | Cesarean SectionUnited States